Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
At a glance
- Drugs Ipilimumab (Primary) ; Paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Jun 2019 Results (n=18) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 08 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Sep 2020.
- 08 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Sep 2019.